ClinicalTrials.gg
Enrolling by invitationNCT07675395Updated Oct 9, 2026

Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)

An interventional study of Pulsed-Field Ablation with FARAWAVE Catheter System in Persistent Atrial Fibrillation, Atrial Fibrillation (AF) and Atrial Remodeling, sponsored by Taipei Veterans General Hospital, Taiwan. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now Enrolling by invitationGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Atrial Fibrillation with a site in Taiwan — 17 open to participants now, 25 under way, 3 of them phase 3. Atrial Fibrillation · Taiwan.

Planned enrollment
60th of 67
30 · median 448
Started
2026
with 6 others
No phase
34 of 95
12 open now
Primary completion
2028-12
later than 17 of 24 live
Registered
93rd of 95
by date
Lead sponsor
4 of 95
Taipei Veterans General Hospital, Taiwan

Among the 95 studies in Atrial Fibrillation with a site in Taiwan, this one is the 60th largest by planned enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2026, is one of 34 with no phase, reaches primary completion later than 17 of the 24 other live ones, and was the 93rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

17 of the 95 studies in Atrial Fibrillation with a site in Taiwan are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Atrial Fibrillation with a site in Taiwan, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.

This is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE / FARADRIVE Catheter and FARASTAR System.

The primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.

Read the detailed description

Background and Rationale Atrial fibrillation (AF) is associated with progressive electrical and structural remodeling of the left atrium. Electrical remodeling typically reverses within a week after restoration of sinus rhythm, whereas structural remodeling takes longer - generally 2 to 4 months - and successful ablation has been shown to improve left atrial transport function. Pre-procedural assessment with echocardiographic left atrial strain and delayed-enhancement MRI may help predict the extent of reverse remodeling after ablation.

Pulsed-field ablation (PFA) is a non-thermal ablation technology that uses pulsed electric fields to create focal lesions selectively targeting cardiomyocytes, while largely sparing surrounding structures such as the esophagus, phrenic nerve, and blood vessels. Compared with radiofrequency ablation (RFA), PFA can create larger and deeper lesions with fewer applications, with a potentially reduced risk of collateral injury. Beyond pulmonary vein isolation (PVI), PFA has also been applied to other atrial substrates, including the posterior wall and mitral line.

A recent study suggested that mean pulmonary arterial pressure did not worsen in patients with pre-existing pulmonary hypertension undergoing repeat PFA for recurrent AF. However, the impact of PFA on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unknown. This study aims to characterize changes in atrial function and structural remodeling 3 to 12 months after PFA for PVI and extensive substrate modification, and to explore its relationship with procedural outcomes.

Study Design This is a prospective, single-center, single-arm observational clinical investigation conducted at Taipei Veterans General Hospital. Thirty patients with persistent AF will undergo the index ablation procedure using the FARAWAVE Catheter, FARADRIVE Catheter, and FARASTAR System (Boston Scientific). Enrollment will cease once approximately 30 subjects have been accrued. An interim endpoint analysis will be performed once all subjects have completed their 6-month follow-up. All participants will be followed for up to 12 months.

Procedure Pre-procedural care will follow the standard institutional protocol for AF ablation cases, with AF classification (paroxysmal vs. non-paroxysmal) defined according to the 2024 HRS consensus on catheter ablation of AF. Pre-procedural evaluation includes transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), cardiac CT and MRI, and 14-day Holter monitoring.

The ablation procedure is performed under deep sedation or general anesthesia, with PFA targeting pulmonary vein isolation and posterior wall isolation. Additional substrate modification may be performed using PFA at the physician's discretion. Conventional invasive hemodynamic assessment of left atrial function - including mean pulmonary artery pressure (mPAP), pulmonary arterial wedge pressure, cardiac output, vascular resistance, and right atrial pressure - will be performed before and after PFA during the procedure.

Post-procedural assessments include 12-lead ECG and in-hospital Holter monitoring within 3 days following PFA. At 3 to 12 months after the procedure, participants will undergo repeat echocardiography, cardiac CT and MRI, ECG, and 14-day Holter monitoring. Invasive hemodynamic assessment will be repeated approximately 3 months after the procedure.

Endpoints The primary endpoint is left atrial structural remodeling, including changes in LA size, atrial strain, extent of atrial fibrosis, and other atrial hemodynamic functions. The secondary endpoint is AF-free survival within 3 to 12 months following PFA. The main scientific question is to elucidate atrial remodeling following non-thermal ablation with PFA and its relationship to ablation outcomes.

Safety Monitoring All adverse events (AEs) and serious adverse events (SAEs) will be captured and classified by the investigator according to relatedness (procedure-related, device-related, cardiovascular-related, arrhythmia-related, heart failure-related), seriousness, timing (pre-procedure, during ablation, post-ablation), and diagnosis. Pre-specified serious adverse events of interest include cardiac tamponade or perforation, death, esophageal perforating complications, gastric motility / pyloric spasm disorders, heart block, myocardial infarction, hospitalization due to cardiovascular or pulmonary PFA system- or procedure-related events, pericarditis, peripheral or organ thromboembolism, pulmonary vein stenosis, severe hemolysis with subsequent renal failure or significant anemia, stroke, transient ischemic attack, unresolved phrenic nerve palsy or paresis, and vascular access complications.

03

Conditions studied

  • Persistent Atrial Fibrillation
  • Atrial Fibrillation (AF)
  • Atrial Remodeling
  • Pulsed Field Ablation

Keywords

  • Pulsed Field Ablation
  • Persistent Atrial Fibrillation
  • Atrial Fibrillation
  • Atrial Remodeling
  • Substrate Modification
  • Atrial Fibrosis
  • Cardiac MRI
  • Posterior Wall Isolation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of persistent atrial fibrillation
  • Left atrial anteroposterior (AP) diameter greater than 4 cm and less than 6 cm
  • Anti-arrhythmic medications (except amiodarone) discontinued for at least 5 half-lives before the procedure
  • No use of beta-blockers or diuretics before or after the ablation procedure
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Paroxysmal atrial fibrillation
  • Previous left atrial surgery or catheter ablation procedure, including left atrial appendage closure
  • Atrial fibrillation due to reversible causes, such as thyroid disorders, acute alcohol intoxication, or other major surgeries within the 90 days preceding the procedure
  • Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass grafting within 90 days of the procedure
  • Known presence of cardiac thrombus
  • Stroke or within the last 90 days
  • Any other anatomical or comorbid condition that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial, comply with follow-up requirements, or impact the scientific validity of the clinical trial results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pulsed-Field Ablation Group

    Subjects with persistent atrial fibrillation undergoing the index ablation procedure with pulsed-field ablation (PFA) for pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. The procedure is performed under deep sedation or general anesthesia using the FARAWAVE Catheter, FARADRIVE Catheter, and FARASTAR System. Invasive hemodynamic assessment (mean pulmonary artery pressure, pulmonary arterial wedge pressure, cardiac output, vascular resistance, right atrial pressure) is performed immediately before and after PFA during the procedure, and repeated approximately 3 months post-procedure. All subjects are followed for 12 months, with structural and functional reassessment by echocardiography, cardiac CT, cardiac MRI, and 14-day Holter monitoring at 3 to 12 months.

    Device: Pulsed-Field Ablation with FARAWAVE Catheter System

Interventions

  • DevicePulsed-Field Ablation with FARAWAVE Catheter System

    Pulsed-field ablation is performed using the FARAWAVE / FARADRIVE Catheter and FARASTAR System (Boston Scientific) under deep sedation or general anesthesia. PFA is delivered to achieve pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. Invasive hemodynamic assessment is performed pre- and post-PFA during the index procedure and repeated at approximately 3 months.

    Also known as: FARAWAVE Catheter, FARADRIVE Catheter, FARASTAR System, FARAPULSE PFA System

06

What researchers measure

Primary outcomes

  1. Change in Left Atrial Anteroposterior Diameter

    Change from baseline in left atrial anteroposterior (AP) diameter measured by transthoracic echocardiography.

    Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure

  2. Change in Left Atrial Volume Index

    Change from baseline in left atrial volume index measured by transthoracic echocardiography.

    Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure

  3. Change in Left Atrial Reservoir Strain

    Change from baseline in left atrial reservoir strain assessed by transthoracic echocardiography with speckle-tracking analysis.

    Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure

  4. Change in Left Atrial Conduit Strain

    Change from baseline in left atrial conduit strain assessed by transthoracic echocardiography with speckle-tracking analysis.

    Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure

  5. Change in Left Atrial Contractile Strain

    Change from baseline in left atrial contractile strain assessed by transthoracic echocardiography with speckle-tracking analysis.

    Time frame: Baseline, 3 months, 6 months, and 12 months post-procedure

  6. Change in Extent of Left Atrial Fibrosis

    Change from baseline in the extent of left atrial fibrosis assessed by delayed-enhancement cardiac magnetic resonance imaging (MRI), expressed as the percentage of fibrotic left atrial wall relative to total left atrial wall area.

    Time frame: Baseline and 3 to 12 months post-procedure

  7. Change in Mean Pulmonary Artery Pressure (mPAP)

    Change from baseline in mean pulmonary artery pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.

    Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure

  8. Change in Pulmonary Arterial Wedge Pressure (PAWP)

    Change from baseline in pulmonary arterial wedge pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.

    Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure

  9. Change in Cardiac Output

    Change from baseline in cardiac output. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.

    Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure

  10. Change in Pulmonary Vascular Resistance

    Change from baseline in pulmonary vascular resistance. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.

    Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure

  11. Change in Right Atrial Pressure

    Change from baseline in right atrial pressure. Invasively measured during cardiac catheterization, performed immediately before and after PFA during the index procedure, and repeated approximately 3 months post-procedure.

    Time frame: Pre-procedure, immediately post-procedure, and 3 months post-procedure

Secondary outcomes

  1. Atrial Fibrillation-Free Survival

    Proportion of subjects free from any documented atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting ≥30 seconds following a 90-day blanking period after the index pulsed-field ablation procedure. Recurrence is assessed by 12-lead ECG and 14-day Holter monitoring performed between 3 and 12 months post-procedure.

    Time frame: 3 to 12 months post-procedure

  2. Correlation Between Atrial Remodeling and Ablation Outcome

    Correlation between post-procedural atrial structural remodeling parameters (left atrial size, atrial strain, extent of atrial fibrosis on delayed-enhancement cardiac MRI, and invasively measured atrial hemodynamic function) and atrial fibrillation-free survival following pulsed-field ablation. Each parameter's association with recurrence is expressed as a correlation coefficient. This analysis aims to identify imaging- and hemodynamic-based predictors of ablation success and to characterize the relationship between reverse atrial remodeling and clinical outcome.

    Time frame: 3 to 12 months post-procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. All study data analysis will be conducted within Taipei Veterans General Hospital, and no external data transfers are planned. Participant data will be anonymized and stored on a secure institutional server accessible only to authorized study personnel.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 29 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 30, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 9, 2026
Contact
No study contact listed any more: removed m•••@gmail.com · •••2121; removed q•••@gmail.com · •••2121
Oct 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Taipei Veterans General Hospital · Taipei, TaiwanContact removed m•••@gmail.com · •••2121Contact removed q•••@gmail.com · •••2121Contact removed (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Enrolling by invitation
    Contact No study contact listed any more: removed m•••@gmail.com · •••2121; removed q•••@gmail.com · •••2121
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Taipei Veterans General Hospital · Taipei, TaiwanContact removed m•••@gmail.com · •••2121Contact removed q•••@gmail.com · •••2121Contact removed (no phone or email listed)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07675395
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jul 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion